| Identification | Back Directory | [Name]
PRT062607 (Hydrochloride) | [CAS]
1370261-97-4 | [Synonyms]
CS-995
BIIB057 HCl
PRT-2607 HCl
PRT062607 HCL
P505-15 hydrochloride
PRT062607 (P505-15 HCL)
PRT062607 (Hydrochloride)
PRT062607 (P505-15, BIIB057) HCl
PRT062607 (Hydrochloride) USP/EP/BP
P505-15, BIIB057 HCl, PRT062607(HCL)
PRT062607 (P505-15, BIIB057) hydrochloride
P505-15 HCl salt, PRT062607 HCl salt,PRT-2607 HCl salt, BIIB-057 HCl salt
P505-15; PRT2607; PRT-2607; PRT 2607; PRT-062607; PRT 062607; P505-15; BIIB057
4-((4-(2H-1,2,3-Triazol-2-yl)phenyl)amino)-2-(((1R,2S)-2-aminocyclohexyl)amino)pyrimidine-5-ca
2-[[(1R,2S)-2-AMinocyclohexyl]aMino]-4-[[3-(2H-1,2,3-triazol-2-yl)phenyl]aMino]-5-pyriMidinecarboxaMide Hydrochloride
4-((4-(2H-1,2,3-Triazol-2-yl)phenyl)amino)-2-(((1R,2S)-2-aminocyclohexyl)amino)pyrimidine-5-carboxamide hydrochloride
2-[[(1R,2S)-2-Aminocyclohexyl]amino]-4-[[3-(2H-1,2,3-triazol-2-yl)phenyl]amino]-5-pyrimidinecarboxamide hydrochloride (1:1)
5-Pyrimidinecarboxamide, 2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-[[3-(2H-1,2,3-triazol-2-yl)phenyl]amino]-, hydrochloride (1:1)
2-[[(1R,2S)-2-Aminocyclohexyl]amino]-4-[[3-(2H-1,2,3-triazol-2-yl)phenyl]amino]-5-pyrimidinecarboxamide hydrochloride (1:1)
PRT062607 (P505-15, BIIB057) HCl | [Molecular Formula]
C19H24ClN9O | [MDL Number]
MFCD28142764 | [MOL File]
1370261-97-4.mol | [Molecular Weight]
429.907 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
≥21.5 mg/mL in DMSO; insoluble in EtOH; ≥83.2 mg/mL in H2O with gentle warming | [form ]
solid |
| Hazard Information | Back Directory | [Uses]
PRT062607 (Hydrochloride)acts as a novel spleen tyrosine kinase (syk) inhibitors used in the treatment of leukemia.
| [target]
Syk | [storage]
Store at -20°C |
|
|